GMED
Globus Medical, Inc.85.79
-0.71-0.82%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Confirms guide conservatism via leases, lumpiness
Q&A largely reaffirms the scripted momentum in U.S. Spine and Enabling Tech but clarifies 2026 guidance conservatism, citing a higher mix of operating leases in capital deals that mute upfront revenue recognition and Nevro's short-term lumpiness despite cross-sell and recruiting focus. Management confirmed Spine growth durability into Q1 2026 via rep conversions and launches, while dismissing recent competitor robotics as reinforcing Excelsius strengths. International lags in APAC but targets 12-15% long-term. Gross margins to hit 69-70%. Deal flexibility drives placements. Investors watch implant pull-through from leases and Nevro ramp.
Key Stats
Market Cap
11.59BP/E (TTM)
27.76Basic EPS (TTM)
3.09Dividend Yield
0%Recent Filings
8-K
Board director resigns immediately
10-K
FY2025 results
Globus Medical drove FY2025 net sales to $2.9B, up 16.7% y/y, with U.S. revenue surging 18.4% to $2.4B on $254M from the Q2 Nevro acquisition and $126M Musculoskeletal Solutions growth, yet Enabling Technologies dipped amid softer placements. Q4 momentum built through Nevro's HFX spinal cord stimulation ramp and 9 new launches like ExcelsiusXR, while margins strengthened post-Nevro inventory step-up amortization. Cash flow hit $753M; $500M buyback authorized with $390M remaining. Nevro integration advanced via restructuring. Supply chain disruptions threaten quarterly momentum.
8-K
Q4 sales surged 25.7%
Globus Medical posted Q4 net sales of $826.4M, up 25.7% year-over-year, fueled by $99.7M from the Nevro acquisition atop 10.6% base business growth. Full-year sales hit $2.94B, with GAAP net income soaring to $537.9M. Q4 crushed expectations. It reaffirmed 2026 revenue guidance at $3.18-3.22B but nudged non-GAAP EPS up to $4.40-4.50.
8-K
Record Q4 sales, 2026 guidance
Globus Medical reported preliminary Q4 2025 sales of $823.2M, up 25.2% from Q4 2024, with full-year sales at $2.936B, up 16.5%. Base business excluding Nevro hit $723.3M, up 10.0%, fueled by US Spine gains and Enabling Technologies peak. Issued 2026 guidance of $3.18B-$3.22B revenue, $4.30-$4.40 non-GAAP EPS. Integration rolls on.
8-K
Q3 sales up 23%
IPO
Employees
Sector
Industry
BVS
Bioventus Inc.
7.52+0.02
CNMD
CONMED Corporation
39.20-1.12
ENOV
Enovis Corporation
26.07-0.47
FZMD
Fuse Medical, Inc.
0.07+0.00
GKOS
Glaukos Corporation
113.76+2.03
INSP
Inspire Medical Systems, Inc.
115.51-3.75
OFIX
Orthofix Medical Inc.
15.55-0.16
OSSFF
EMBLA MEDICAL
5.33+0.00
SIBN
SI-BONE, Inc.
19.42+1.01
ZBH
Zimmer Biomet Holdings, Inc.
90.91-1.52